RxDoctor Payments Data

Navneet Dullet, MD

Clinical Cardiac Electrophysiology · Modesto, CANPI 1073680971

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (55.1%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Abbott at 45.8% of the total. That places this record below the midpoint for clinical cardiac electrophysiology clinicians in CA, where the typical reported total is $26,911.

$11,620in general payments, 2019–2025

Across 223 payments — averaging $52.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$5K
  • Medtronic$4K
  • Boston Scientific$2K
  • Johnson & Johnson$143
  • Biotronik Inc.$73
  • Edwards Lifesciences$60
  • plus $213 from 6 others

What the payments were for

  • Travel & lodging$6,40455%
  • Food & beverage$5,14644%
  • Education$701%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,620 in reported general payments places this provider in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

See all clinical cardiac electrophysiology providers in California →

Medicare billing

Part B allowed, 2024
$232,233
Medicare patients
988
Services billed
2,972

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban181$184,772
XareltoRivaroxaban109$118,233
JardianceEmpagliflozin13$13,512
Dofetilide39$7,350
Amiodarone Hcl100$4,835
SotalolSotalol Hcl173$3,457
Metoprolol Succinate196$3,087
Atorvastatin Calcium132$1,227
ClopidogrelClopidogrel Bisulfate80$1,165
Losartan Potassium130$1,049
Flecainide Acetate37$1,000
Potassium Chloride36$790
Rosuvastatin Calcium57$765
Sotalol AfSotalol Hcl17$716
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$713

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$143$118,233109 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 25th percentile of 290 clinical cardiac electrophysiology providers in California.

Other clinical cardiac electrophysiology in Modesto

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →